Prediction of Weight Loss and Regain Following Dietary, Lifestyle, and Pharmacologic Intervention
| Autor: | Maysoon Elkhawad, Antonella Napolitano, B. Delafont, Samuel Virtue, Chong Yew Tan, Derek J. Nunez, Antonio Vidal-Puig, Sam R. Miller, Peter R. Murgatroyd, A Brooke |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Diet Reducing Psychological intervention Weight Gain Satiety Response Pharmacologic intervention law.invention Eating Absorptiometry Photon Insulin resistance Recurrence law Weight loss Appetite Depressants Weight Loss medicine Humans Pharmacology (medical) Obesity Exercise Life Style Pharmacology Clinical pharmacology business.industry Body Weight Weight change Calorimetry Indirect medicine.disease Magnetic Resonance Imaging Body Composition Physical therapy Female Insulin Resistance medicine.symptom business Cyclobutanes Forecasting Sibutramine medicine.drug |
| Zdroj: | Clinical Pharmacology & Therapeutics. 91:1027-1034 |
| ISSN: | 1532-6535 0009-9236 |
| Popis: | To develop statistical models for predicting weight loss and regain, we analyzed the phenotypic responses in an outpatient study of 60 obese subjects randomized to one of three 12-week interventions, diet (–600 kcal) alone, diet with exercise, and diet with sibutramine. This was followed by 12 weeks of observation. The best of the “baseline covariates” models was one that incorporated intervention group and baseline homeostasis model assessment–estimated insulin resistance (HOMAIR). It predicted week 12 weight change with R2 of 0.38 and root mean square error (√MSE) of 2.92 kg. An alternative model incorporating baseline fat mass plus change in weight and HOMAIR at week 4 improved the prediction (R2, 0.67, √MSE, 2.19 kg). We could not identify a satisfactory model to predict weight regain. We conclude that prediction of weight loss over 12 weeks is significantly improved when short-term weight change is incorporated into the model. This information could be utilized to forecast the success of a weight-loss program and to motivate and contribute to innovative designing of obesity trials. Clinical Pharmacology & Therapeutics (2012); 91 6, 1027–1034. doi:10.1038/clpt.2011.333 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text